Colorectal Neoplasm Clinical Trial
Official title:
PhaseⅠClinical Study of Recombinant Human Endostatin in Combination With mFOLFOX6 as Initial Therapy for Patients With Metastatic Colorectal Cancer
NCT number | NCT01310478 |
Other study ID # | SIM-85 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 1 |
First received | March 7, 2011 |
Last updated | March 7, 2011 |
Start date | August 2010 |
To investigate safety and tolerance of dose-escalation of infusional recombinant human endostatin in combination with mFOLFOX6 as initial therapy for patients with metastatic colorectal cancer.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | |
Est. primary completion date | May 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 17 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Provision of written informed consent 2. Histological or cytological confirmed adenocarcinoma of the colon or rectum 3. Age between 18 and 70 years. 4. Patients must have received no prior systemic therapy for metastatic disease. Anyadjuvant/neoadjuvant oxaliplatin therapy must have been received >12 months prior to study entry and adjuvant/neoadjuvant 5-FU must have been received >6 months prior to study entry. Patients who have previously been disease free following a neoadjuvant chemotherapy regimen and resection of all primary tumour and metastatic disease are eligible.. 5. ECOG Performance Status of 0 or1 6. Life expectancy of at least 12 weeks 7. The required evidence of measurable lesions should be at least 10 mm in the longest diameter by spiral computed tomography scan or 20 mm with conventional techniques (RECIST criteria) 8. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening: - Hemoglobin > 9.0 g/dl - Absolute neutrophil count (ANC) >1,500/mm3 - Platelet count 100,000/µl - Total bilirubin < 1.5 times the upper limit of normal ALT and AST < 2.5 x ULN(< 5 x ULN for patients with liver involvement of their cancer) - ALP< 4 x ULN - PT-INR/PTT < 1.5 x upper limit of normal - Serum creatinine < 1.5 x ULN Exclusion Criteria: 1. History of cardiac disease: - congestive heart failure >NYHA class 2 - with a history of symptomatic coronary artery disease(including angina and myocardial infarction) or other ischemic heart disease - cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension 2. History of HIV infection or chronic hepatitis B or C (high copy number of HBV). 3. Active clinically serious infections (> grade 2 NCI-CTC version 3.0) 4. Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry) 5. Patients with seizure disorder requiring medication (such as steroids or anti-epileptics) 6. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma within 5 years. 7. Recent (<28 days) major thoracic or abdominal surgery prior to entry into the studyor a surgical incision that is not fully healed 8. Known hypersensitivity to recombinant human endostatin, oxaliplatin, 5-FU, leucovorin, capecitabine or any of the excipients of these products 9. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results. 10. Peripheral neuropathy =CTC grade 2 11. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study 12. Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial (and men for at least 3 months after last administration of study medication). |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Shanghai Cancer Center | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Fudan University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose limiting toxicity and maximum tolerance dose of continous intravenous Endostar in combination with mFOLFOX6 | 14 days | Yes | |
Secondary | Parameters of human pharmacokinetics of continous intravenous Endostar in combination with mFOLFOX6 | 11 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02244632 -
Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01417611 -
The Usefulness of I-scan in Screening Colonoscopy
|
N/A | |
Completed |
NCT02057471 -
Intravenous Iron: Measuring Response in Anemic Surgical Patients
|
Phase 4 | |
Terminated |
NCT01074333 -
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
|
N/A | |
Active, not recruiting |
NCT00506207 -
A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy
|
Phase 1 | |
Recruiting |
NCT05953662 -
Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer
|
N/A | |
Completed |
NCT01959269 -
Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
|
N/A | |
Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT04160832 -
Prevalence and Spectrum of Cancer Susceptibility Among Patients With Advanced Colorectal Polyps
|
||
Terminated |
NCT02961283 -
Study of ASN003 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Suspended |
NCT02121405 -
Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM
|
Phase 3 | |
Active, not recruiting |
NCT03936530 -
Infrapyloric and Greater Curvature Lymph Node Metastasis in Colon Cancer
|
||
Terminated |
NCT03724071 -
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02882620 -
Enhancing Prevention Pathways Toward Tribal Colorectal Health
|
N/A | |
Completed |
NCT00906997 -
Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy
|
N/A | |
Completed |
NCT00188331 -
Cognitive Function and Fatigue in Colorectal Cancer (CRC) Patients After Chemotherapy
|
N/A | |
Completed |
NCT04786704 -
A Stool DNA Test for Detection of Advanced Colorectal Neoplasia in Asymptomatic Chinese Community Population
|
||
Terminated |
NCT02384850 -
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
|
Phase 1 | |
Completed |
NCT01288833 -
Clinical Study of Real Time Colorectal Polyp Diagnosis During Colonoscopy - the VALID Colonoscopy Study
|
N/A | |
Completed |
NCT00001693 -
Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
|
Phase 1 |